Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -0.58 is 27% below its 5-year average of -0.46, around the middle of its 5-year range (-0.84–-0.25).
14.85% below its 12-month average of -0.51.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -0.16.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
EARNINGS PER SHARE (EPS)
-0.58
EARNINGS PER SHARE (EPS) AVG TTM
-0.51
EARNINGS PER SHARE (EPS) AVG 3Y
-0.40
EARNINGS PER SHARE (EPS) AVG 5Y
-0.46
EARNINGS PER SHARE (EPS) AVG 10Y
-2.68
EARNINGS PER SHARE (EPS) AVG 15Y
-10.90
EARNINGS PER SHARE (EPS) AVG 20Y
-20.83
CURRENT VS TTM AVG
-14.85%
CURRENT VS 3Y AVG
-45.91%
CURRENT VS 5Y AVG
-26.55%
CURRENT VS 10Y AVG
+78.33%
CURRENT VS 15Y AVG
+94.68%
CURRENT VS 20Y AVG
+97.22%
Savara Inc.
Market Cap
$952.91M
Earnings Per Share (EPS)
-0.58
TTM Avg
-0.51
3Y Avg
-0.40
5Y Avg
-0.46
Market Cap
$953.81M
Earnings Per Share (EPS)
-1.05
TTM Avg
-1.23
3Y Avg
-0.94
5Y Avg
-0.94
Market Cap
$934.79M
Earnings Per Share (EPS)
-3.37
TTM Avg
-2.60
3Y Avg
-2.33
5Y Avg
-2.16
Market Cap
$973.93M
Earnings Per Share (EPS)
0.35
TTM Avg
-0.99
3Y Avg
-0.18
5Y Avg
0.61
Market Cap
$929.83M
Earnings Per Share (EPS)
N/A
TTM Avg
-1.94
3Y Avg
-1.94
5Y Avg
-1.94
Market Cap
$978.09M
Earnings Per Share (EPS)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$981.66M
Earnings Per Share (EPS)
0.71
TTM Avg
-1.77
3Y Avg
-1.98
5Y Avg
-1.86
Market Cap
$923.53M
Earnings Per Share (EPS)
-1.76
TTM Avg
-1.29
3Y Avg
-1.36
5Y Avg
-1.36
Market Cap
$982.46M
Earnings Per Share (EPS)
-2.97
TTM Avg
-9.41
3Y Avg
-6.16
5Y Avg
-6.16
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Savara Inc. (SVRA) | $952.91M | -0.58 | -0.51 | -0.40 | -0.46 |
| Aktis Oncology, Inc. (AKTS)vs › | $953.81M | -1.05 | -1.23 | -0.94 | -0.94 |
| Kura Oncology, Inc. (KURA)vs › | $934.79M | -3.37 | -2.60 | -2.33 | -2.16 |
| Pacira BioSciences, Inc. (PCRX)vs › | $973.93M | 0.35 | -0.99 | -0.18 | 0.61 |
| Seaport Therapeutics, Inc. Common Stock (SPTX)vs › | $929.83M | N/A | -1.94 | -1.94 | -1.94 |
| Latigo Biotherapeutics Inc. (LTGO)vs › | $978.09M | N/A | N/A | N/A | N/A |
| MeiraGTx Holdings plc (MGTX)vs › | $981.66M | 0.71 | -1.77 | -1.98 | -1.86 |
| CeriBell, Inc. (CBLL)vs › | $923.53M | -1.76 | -1.29 | -1.36 | -1.36 |
| LB Pharmaceuticals Inc Common Stock (LBRX)vs › | $982.46M | -2.97 | -9.41 | -6.16 | -6.16 |
| MoonLake Immunotherapeutics (MLTX)vs › | $921.06M | -3.85 | -2.71 | -1.96 | -1.55 |
Trailing EPS (TTM)
$-0.58
Forward EPS (Est.)
$-0.94
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -0.53 |
| 2024-12-31 | -0.48 |
| 2023-12-31 | -0.33 |
| 2022-12-31 | -0.25 |
| 2021-12-31 | -0.32 |
| 2020-12-31 | -0.84 |
| 2018-12-31 | -1.85 |
| 2017-12-31 | -1.70 |
| 2016-12-31 | -3.27 |
| 2015-12-31 | -17.19 |
| 2014-12-31 | -16.41 |
| 2013-12-31 | -19.63 |
| 2012-12-31 | -22.86 |
| 2011-12-31 | -32.94 |
| 2010-12-31 | -44.88 |
| 2009-12-31 | -169.85 |
| 2008-12-31 | -516.69 |
| 2007-12-31 | -430.96 |
| 2006-12-31 | -693.77 |
| 2005-12-31 | -724.89 |
| 2004-12-31 | -231.21 |
| 2003-12-31 | -120.54 |
| 2002-12-31 | -235.41 |
| 2001-12-31 | -1960.07 |
| 2000-12-31 | -0.08 |
